Literature DB >> 33579217

High fascin-1 expression in colorectal cancer identifies patients at high risk for early disease recurrence and associated mortality.

Athanasios Tampakis1,2, Ekaterini-Christina Tampaki3, Afrodite Nonni4, Ioannis D Kostakis3, Alberto Posabella5, Konstantinos Kontzoglou3, Markus von Flüe5, Evangelos Felekouras6, Gregory Kouraklis3, Nikolaos Nikiteas3.   

Abstract

BACKGROUND: Fascin is the main actin cross-linker protein that regulates adhesion dynamics and stabilizes cell protrusion, such as filopodia. In human cancer, fascin expression correlates with aggressive clinical features. This study aimed to determine the expression patterns of fascin-1 and assessed its prognostic significance in colorectal cancer.
METHODS: One hundred eleven specimens of patients with primary resectable colorectal cancer were examined via immunohistochemistry for the expression of fascin-1, and the results were correlated with clinicopathological characteristics and survival data.
RESULTS: Fascin-1 staining displayed strong intensity in the cytoplasm of the colorectal cancer cells and endothelial cells of tumor blood vessels. Moderate to high fascin-1 expression was associated with progressive anatomic disease extent (p < 0.001), higher T classification (p = 0.007), the presence of lymph node (p < 0.001) and distant metastasis (p = 0.002), high grade tumors (p = 0.002) and vascular invasion (p < 0.001). Patients displaying moderate and high fascin-1 expression demonstrated a significantly worse 5-year overall survival [HR; 3.906, (95%CI) = 1.250-12.195] and significantly worse 3-year progression-free survival [HR; 3.448, (95%CI) = 1.401-8.475] independent of other clinicopathological characteristics. Besides, high fascin-1 expression in early-stage cancer only was associated with a dismal prognosis.
CONCLUSIONS: High fascin-1 expression in colorectal cancer is an independent negative prognostic factor for survival, increasing the risk for disease recurrence or death almost by sevenfold. Fascin-1 expression could be potentially utilized to identify high-risk patients prone to metastasis already in early-stage disease.

Entities:  

Keywords:  Cancer stem cells; Colorectal cancer; Cytoskeleton; Fascin-1

Mesh:

Substances:

Year:  2021        PMID: 33579217      PMCID: PMC7881491          DOI: 10.1186/s12885-021-07842-4

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  44 in total

Review 1.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

2.  Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.

Authors:  Dimitrios Iliopoulos; Heather A Hirsch; Guannan Wang; Kevin Struhl
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

Review 3.  The therapeutic promise of the cancer stem cell concept.

Authors:  Natasha Y Frank; Tobias Schatton; Markus H Frank
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

Review 4.  Cancer stem cells in solid tumors.

Authors:  Laurie E Ailles; Irving L Weissman
Journal:  Curr Opin Biotechnol       Date:  2007-10       Impact factor: 9.740

Review 5.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

6.  Heterogeneity in cancer: cancer stem cells versus clonal evolution.

Authors:  Mark Shackleton; Elsa Quintana; Eric R Fearon; Sean J Morrison
Journal:  Cell       Date:  2009-09-04       Impact factor: 41.582

Review 7.  Cancer stem cells: a model in the making.

Authors:  Lauren L Campbell Marotta; Kornelia Polyak
Journal:  Curr Opin Genet Dev       Date:  2009-01-21       Impact factor: 5.578

Review 8.  The increasing complexity of the cancer stem cell paradigm.

Authors:  Jeffrey M Rosen; Craig T Jordan
Journal:  Science       Date:  2009-06-26       Impact factor: 47.728

9.  Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.

Authors:  A Lugli; G Iezzi; I Hostettler; M G Muraro; V Mele; L Tornillo; V Carafa; G Spagnoli; L Terracciano; I Zlobec
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

10.  Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells.

Authors:  Matthew J Grimshaw; Lucienne Cooper; Konstantinos Papazisis; Julia A Coleman; Hermann R Bohnenkamp; Laura Chiapero-Stanke; Joyce Taylor-Papadimitriou; Joy M Burchell
Journal:  Breast Cancer Res       Date:  2008-06-09       Impact factor: 6.466

View more
  3 in total

1.  Correction to: High fascin-1 expression in colorectal cancer identifies patients at high risk for early disease recurrence and associated mortality.

Authors:  Athanasios Tampakis; Ekaterini-Christina Tampaki; Afrodite Nonni; Ioannis D Kostakis; Alberto Posabella; Konstantinos Kontzoglou; Markus von Flüe; Evangelos Felekouras; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  BMC Cancer       Date:  2021-02-24       Impact factor: 4.430

Review 2.  Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing.

Authors:  Talal El Zarif; Marcel Yibirin; Diana De Oliveira-Gomes; Marc Machaalani; Rashad Nawfal; Gianfranco Bittar; Hisham F Bahmad; Nizar Bitar
Journal:  Cancers (Basel)       Date:  2022-04-23       Impact factor: 6.575

3.  Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study.

Authors:  Octavian Sabin Tătaru; Orsolya Martha; Felice Crocetto; Biagio Barone; Septimiu Voidazan; Angela Borda; Anca Sin; Adina Hutanu; Andrada Loghin; Ileana Sin; Daniel Porav-Hodade; Calin Bogdan Chibelean; Liliana Vartolomei; Giuseppe Lucarelli; Matteo Ferro; Virgil Gheorghe Osan; Carlo Buonerba; Mihai Dorin Vartolomei
Journal:  Future Sci OA       Date:  2021-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.